It was approved in 2019 to treat depression, but some medical professionals say the treatment flew under the radar during the pandemic. It’s a nasal spray treatment that consists of a drug ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

(MENAFN - EIN Presswire) Spravat (esketamine) FastTrack Program by Ketamine Academy Live, step-by-step program to help clinics get certified, operational, and reimbursed for Spravato®-without the ...

Elizabeth Haase, MD, former chair of the American Psychiatric Association's Committee on Climate Change, shared her advice ...

A ketamine derivative, esketamine under the brand name Spravato, is FDA-approved as a nasal spray to treat depression in adults, according to the National Institute on Drug Abuse.

Due in part to recent reports about Matthew Perry and Elon Musk, ketamine seems to be taking up more and more space in the conversation about substance abuse. But despite its recent spike in ...

Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, ...

Johnson & Johnson developed its own ketamine-derived treatment for depression (esketamine, sold as a nasal spray called Spravato) that received FDA approval in 2019, the first of its kind.